Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
IPO Year: 2022
Exchange: NYSE
Website: https://www.bausch.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/10/2024 | $19.00 | Outperform | Raymond James |
5/6/2024 | $16.00 → $18.00 | Equal-Weight → Overweight | Morgan Stanley |
1/4/2024 | $19.00 → $17.00 | Outperform → In-line | Evercore ISI |
12/12/2023 | $16.00 | Hold | Stifel |
10/3/2023 | $20.00 | Outperform | Evercore ISI |
5/30/2023 | $20.00 | Equal-Weight | Morgan Stanley |
3/9/2023 | Hold | Needham | |
12/21/2022 | $17.00 | Equal Weight | Barclays |
9/12/2022 | $21.00 | Buy | H.C. Wainwright |
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
Revenue of $1.216 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $151 Million Adjusted EBITDA (non-GAAP)1 of $209 Million Revenue Grew 17% as Reported and 20% on a Constant Currency1 Basis Compared to the Second Quarter of 2023, Driven by Broad-Based Growth Across All Business Segments Raising Full-Year 2024 Revenue and Adjusted EBITDA (non-GAAP)1 Guidance Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2024 financial results. "Our continued growth is being fueled by a relentless focus on selling and operational excellence, and a commitmen
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2024 financial results on Wednesday, July 31, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, July 31, 2024 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/49632 Participant
Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22. Data presentations highlight the results of several studies evaluating consumer, pharmaceutical and vision care products from the company's broad eye care portfolio, in addition to evaluations of the dry eye treatment landscape and over
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company's proprietary OpticAlign® design, INFUSE for Astigmatism provides astigmatic patients clear, stable vision, all-day comfort and minimizes contact lens dryness. The company expects to start shipping INFUSE for Astigmatism fitting sets to eye care professionals in July 2024. "More than half of toric lens wearers with astigmatism experience contact lens dryn
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter supplement that targets the key root causes of dry eyes, promotes healthy tear production and provides noticeable relief of eye dryness symptoms in as little as two to four weeks.1,2* "We offer dry eye sufferers a wide array of options that target the ocular surface, but many consumers are looking for options that go beyond eye drops," said John Ferris, executive vice president, Consumer, Bausch + Lomb. "With Blink NutriTears, consumers now have a first-of-its-kind clinical
Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the "Annual Meeting") held on May 29, 2024. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Nathalie Bernier 344,550,519 28,790 3,089,749 Gary Hu 344,514,922 64,387 3,089,749 Brett Icahn 344,321,103 258,206 3,089,749 Sarah B. Kavanagh 343,504,035
15 ePosters and In-Person Presentations Will Include Clinical Data on Blink™ NutriTears® Supplement for Dry Eyes, Blink® Triple Care Lubricating Eye Drops and MIEBO® (Perfluorohexyloctane Ophthalmic Solution) Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 12 ePosters during the American Optometric Association (AOA) Optometry's Meeting ePoster Session, taking place virtually May 29-30, 2024. The company will also have three live presentations and host nine education events during the in-person meeting, taking place in Nashville June 19-22, 2024. The OnDemand ePosters will
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. "enVista Envy is the next step in the dramatic transformation of our IOL portfolio," said Luc Bonnefoy, president, Global Surgical, Bausch + Lomb. "This first premium IOL on the enVista platform follows the U.S. launch of enVista Aspire™ late last year. The company plans to launch
Revenue of $1.099 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million Adjusted EBITDA (non-GAAP)1 of $180 Million Revenue Grew 18% as Reported and 20% on a Constant Currency1 Basis Compared to the First Quarter of 2023, Driven by Growth Across All Business Segments Foreign Exchange Negatively Impacted Revenue by Approximately $20 Million Raising Full-Year 2024 Constant Currency Revenue Growth1 Guidance Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2024 financial results. "Outperformance from each of our business units and solid
21 Poster Presentations include Evaluations of Consumer, Pharmaceutical, Surgical and Vision Care Products and Pipeline Programs, Including a Novel Dry Eye Nutritional Supplement Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Seattle May 5-9, 2024. The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company's broad eye care portfolio, as well as pipeline innovat
SC 13G - Bausch & Lomb Corp (0001860742) (Subject)
S-8 - Bausch & Lomb Corp (0001860742) (Filer)
10-Q - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
10-Q - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
ARS - Bausch & Lomb Corp (0001860742) (Filer)
DEF 14A - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
10-K - Bausch & Lomb Corp (0001860742) (Filer)
Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai
Mr. Bailey and Mr. Stewart Will Join Bausch + Lomb on April 24, 2023 Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company. Concurrent with these appointments, Christina Ackermann will step down from her role as EVP, General Counsel and president, Ophthalmic Pharmaceuticals, and will leave Bausch + Lomb on April
SparingVision appoints Joseph C. Papa as Chairman Former Bausch and Lomb Chairman and CEO joins as non-executive independent Chairman as SparingVision enters the clinic with first gene agnostic lead program SPVN06 Paris, April 5, 2023 – SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, today announces the appointment of Joseph C. Papa as its independent Chairman. Papa brings over 30 years of experience in the healthcare sector, having most recently served as Chief Executive Officer and Chairman at Bausch and Lomb Corporation ("Bausch and Lomb") (NYSE:BLCO) a global eye health company. During his tenure, Papa successfully led
Mr. Saunders Brings More Than 25 Years of Health Care Leadership to Bausch + Lomb Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer ("CEO") and chair of the Board of Directors ("Board") of the Company, effective March 6, 2023. Concurrent with this appointment, and as previously announced, Joseph C. Papa will step down from his roles as CEO and director. Additionally, effective upon Mr. Saunders' appointment as chair of the Board, Thomas W. Ross, Sr. will become the Lead Independent Director of the Board. To
Raymond James initiated coverage of Bausch + Lomb with a rating of Outperform and set a new price target of $19.00
Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $18.00 from $16.00 previously
Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $17.00 from $19.00 previously
Stifel initiated coverage of Bausch + Lomb with a rating of Hold and set a new price target of $16.00
Evercore ISI resumed coverage of Bausch + Lomb with a rating of Outperform and set a new price target of $20.00
Morgan Stanley resumed coverage of Bausch + Lomb with a rating of Equal-Weight and set a new price target of $20.00
Needham initiated coverage of Bausch + Lomb with a rating of Hold
Barclays initiated coverage of Bausch + Lomb with a rating of Equal Weight and set a new price target of $17.00
H.C. Wainwright initiated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $21.00
Revenue of $1.216 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $151 Million Adjusted EBITDA (non-GAAP)1 of $209 Million Revenue Grew 17% as Reported and 20% on a Constant Currency1 Basis Compared to the Second Quarter of 2023, Driven by Broad-Based Growth Across All Business Segments Raising Full-Year 2024 Revenue and Adjusted EBITDA (non-GAAP)1 Guidance Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2024 financial results. "Our continued growth is being fueled by a relentless focus on selling and operational excellence, and a commitmen
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2024 financial results on Wednesday, July 31, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, July 31, 2024 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/49632 Participant
Revenue of $1.099 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million Adjusted EBITDA (non-GAAP)1 of $180 Million Revenue Grew 18% as Reported and 20% on a Constant Currency1 Basis Compared to the First Quarter of 2023, Driven by Growth Across All Business Segments Foreign Exchange Negatively Impacted Revenue by Approximately $20 Million Raising Full-Year 2024 Constant Currency Revenue Growth1 Guidance Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2024 financial results. "Outperformance from each of our business units and solid
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, May 1, 2024 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/49631 Participant Event Dial-in:
Fourth-Quarter 2023 Financial Results Revenue of $1.173 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $54 Million Adjusted EBITDA (non-GAAP)1 of $231 Million Revenue Grew 18% as Reported and 19% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2022, Driven by Growth Across All Segments Full-Year 2023 Financial Results Revenue of $4.146 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $260 Million Adjusted EBITDA (non-GAAP)1 of $738 Million Revenue Grew 10% as Reported and 12% on a Constant Currency1 Basis Compared to the Full Year of 2022, Driven by Growth Across All Segments Foreign Exchange Negatively Im
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 21, 2024 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/49630 Participant
Revenues of $1.007 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $84 Million Adjusted EBITDA (non-GAAP)1 of $187 Million Revenues Grew 7% as Reported and 8% on a Constant Currency1 Basis Compared to the Third Quarter of 2022, Driven by Growth in the Vision Care and Surgical Segments Foreign Exchange Negatively Impacted Revenues and Adjusted EBITDA (non-GAAP)1 by Approximately $10 Million and $14 Million, Respectively Raises Full-Year Revenue and Adjusted EBITDA (non-GAAP)1 Guidance Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2023 fina
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2023 financial results on Wednesday, Nov. 1, 2023. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Nov. 1, 2023 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/47447 Participant Event Dial-in:
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2023 financial results on Wednesday, Aug. 2, 2023. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Aug. 2, 2023 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/47446 Participant Event Dial-in: +1
Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2023 financial results on Wednesday, May 3, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, May 3, 2023 Time: 8:00 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/47444 Participant Ev
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC
Raymond James analyst Gary Nachman initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Outperform rating and announces Price Target of $19.
Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and raises the price target from $15 to $15.5.
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space. Oppenheimer writes, “We consider Clearside a pioneer in suprachoroidal delivery via its suprachoroidal Microinjector that improves delivery of therapies for retinal diseases.” Suprachoroidal drug delivery is an ocular route of drug administration. The analyst writes that intravitreal injections have traditionally been the standard for delivering retinal treatments, but they can cause issues like uncontrolled dispersion. Meanwhile, SCS injections provide a more targeted and compartmental
15 ePosters and In-Person Presentations Will Include Clinical Data on Blink™ NutriTears® Supplement for Dry Eyes, Blink® Triple Care Lubricating Eye Drops and MIEBO® (Perfluorohexyloctane Ophthalmic Solution)Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 12 ePosters during the American Optometric Association (AOA) Optometry's Meeting ePoster Session, taking place virtually May 29-30, 2024. The company will also have three live presentations and host nine education events during the in-person meeting, taking place in Nashville June 19-22, 2024.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush raised the price target for BJ’s Restaurants, Inc. (NASDAQ:BJRI) from $40 to $43. Wedbush analyst Nick Setyan maintained an Outperform rating. BJ’s Restaurants shares rose 5.9% to close at $34.68 on Friday. See how other analysts view this stock. Mizuho boosted the price target for Robinhood Markets, Inc (NASDAQ:HOOD) from $20 to $21. Mizuho analyst Dan Dolev maintained a Buy rating. Robinhood shares rose 1.9% to close at $17.95 on Friday. See how other analysts view this stock. B of A
Morgan Stanley analyst Patrick Wood upgrades Bausch & Lomb (NYSE:BLCO) from Equal-Weight to Overweight and raises the price target from $16 to $18.
HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and maintains $20 price target.